within Pharmacolibrary.Drugs.ATC.L;

model L01EX07
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.34,
    Cl             = 3.733333333333334e-05,
    adminDuration  = 600,
    adminMass      = 60 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.349,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0007166666666666666,
    Tlag           = 60,            
    Vdp             = 1.324,
    k12             = 24.5,
    k21             = 24.5
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01EX07</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Cabozantinib is an oral multi-kinase inhibitor that targets MET, VEGFR, and other tyrosine kinases. It is approved for the treatment of advanced renal cell carcinoma, hepatocellular carcinoma, and medullary thyroid cancer.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult patients with advanced solid tumors. Parameters from population pharmacokinetic analyses in clinical studies involving both male and female patients.</p><h4>References</h4><ol><li><p>Campbell, MT, et al., &amp; Habra, MA (2024). Cabozantinib monotherapy for advanced adrenocortical carcinoma: a single-arm, phase 2 trial. <i>The Lancet. Oncology</i> 25(5) 649–657. DOI:<a href=&quot;https://doi.org/10.1016/S1470-2045(24)00095-0&quot;>10.1016/S1470-2045(24)00095-0</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38608694/&quot;>https://pubmed.ncbi.nlm.nih.gov/38608694</a></p></li><li><p>Nguyen, L, et al., &amp; Lacy, S (2016). Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Cabozantinib. <i>Journal of clinical pharmacology</i> 56(9) 1130–1140. DOI:<a href=&quot;https://doi.org/10.1002/jcph.714&quot;>10.1002/jcph.714</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26865195/&quot;>https://pubmed.ncbi.nlm.nih.gov/26865195</a></p></li><li><p>Castellano, D, et al., &amp; Jonasch, E (2020). Exposure-response modeling of cabozantinib in patients with renal cell carcinoma: Implications for patient care. <i>Cancer treatment reviews</i> 89 102062–None. DOI:<a href=&quot;https://doi.org/10.1016/j.ctrv.2020.102062&quot;>10.1016/j.ctrv.2020.102062</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32659623/&quot;>https://pubmed.ncbi.nlm.nih.gov/32659623</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01EX07;
